References
- Afridi, S. K., Minas, H., Afridi, N. K., Fatima, S., & Chopra, P. (2010). Community mental health in Peshawar, the need to reform. Journal of Ayub Medical College Abbottabad, 22(4), 210–214.
- Ahmad, I., Khalily, M. T., Hallahan, B., & Shah, I. (2017). Factors associated with psychotic relapse in patients with schizophrenia in a Pakistani cohort. International Journal of Mental Health Nursing, 26(4), 384–390. doi: 10.1111/inm.12260
- American Psychological Association. (2013). Diagnostic and statistical manual of mental disorders (DSM-5®). Washington, DC: American Psychiatric Pub.
- Angermeyer, M. C., Kühn, L., Goldstein, J. M. (1990). Gender and the course of schizophrenia: differences in treated outcomes. Schizophrenia Bulletin, 16(2), 293–307.
- Aparasu, R. R., Bhatara, V., & Gupta, S. (2005). U.S. national trends in the use of antipsychotics during office visits, 1998-2002. Annals of Clinical Psychiatry, 17(3), 147–152.
- Castle, D. J., & Murray, R. M. (1991). The neurodevelopmental basis of sex differences in schizophrenia. Psychological Medicine, 21(03), 565–575.
- Chandra, I. S., Kumar, K. L., Reddy, M. P., & Reddy, C. M. P. K. (2014). Attitudes toward medication and reasons for non-compliance in patients with schizophrenia. Indian Journal of Psychological Medicine, 36(3), 294. doi: 10.4103/0253-7176.135383.
- Cramer, J. A., & Rosenheck, R. (2006). Compliance with medication regimens for mental and physical disorders. Psychiatric Services, 49, 196–201. doi: 10.1176/ps.49.2.196.
- Da Silva, T. L., & Ravindran, A. V. (2015). Contribution of sex hormones to gender differences in schizophrenia: a review. Asian Journal of Psychiatry, 18, 2–14. doi: 10.1016/j.ajp.2015.07.016.
- Davis, K. L. (1984). A family history study of schizophrenia-related personality disorders. American Journal of Psychiatry, 141(3), 424–427.
- Day, J. C., Wood, G., Dewey, M., & Bentall, R. P. (1995). A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients. The British Journal of Psychiatry, 166(5), 650–653.
- Falkenburg, J., & Tracy, D. K. (2014). Sex and schizophrenia: a review of gender differences. Psychosis, 6(1):61–69. doi: 10.1080/17522439.2012.733405.
- Farooqi, Y. N. (2006). Traditional healing practices sought by Muslim psychiatric patients in Lahore, Pakistan. International Journal of Disability, Development and Education. 53(4), 401–415. doi: 10.1080/10349120601008530.
- Fleischhacker, W. W., & Uchida, H. (2014). Critical review of antipsychotic polypharmacy in the treatment of schizophrenia. International Journal of Neuropsychopharmacology, 17(7), 1083–1093. doi: 10.1017/S1461145712000399.
- Flor-Henry, P. (1990). Influence of gender in schizophrenia as related to other psychopathological syndromes. Schizophrenia Bulletin, 16(2), 211–227.
- Freedman, R. (2005). The choice of antipsychotic drugs for schizophrenia. New England Journal of Medicine, 353(12), 1286. doi: 10.1056/NEJMe058200.
- Frith, C. D. (2014). The cognitive neuropsychology of schizophrenia. London (UK): Psychology Press.
- Gadit, A. A. M. (2007). Psychiatry in Pakistan: 1947-2006: A new balance sheet. JPMA, 57(9), 453–463.
- Gianfrancesco, F. D., Rajagopalan, K., Sajatovic, M., & Wang, R.-H. (2006). Treatment adherence among patients with schizophrenia treated with atypical and typical antipsychotics. Psychiatry Research, 144(2), 177–189. doi: 10.1016/j.psychres.2006.02.006.
- Gogos, A., Sbisa, A. M., Sun, J., Gibbons, A., Udawela, M., & Dean, B. (2015). A role for estrogen in schizophrenia: Clinical and preclinical findings. International Journal of Endocrinology, 2015, 615356. doi: 10.1155/2015/615356.
- Goldstein, M. J., & Miklowitz, D. J. (1995). The effectiveness of psychoeducational family therapy in the treatment of schizophrenic disorders. Journal of Marital and Family Therapy, 21(4), 361–376.
- Hambrecht, M., Maurer, K., & Häfner, H. (1993). Evidence for a gender bias in epidemiological studies of schizophrenia. Schizophrenia Research, 8(3), 223–231.
- Harrison, P. J., & Weinberger, D. R. (2005). Schizophrenia genes, gene expression, and neuropathology: On the matter of their convergence. Molecular Psychiatry, 10, 40–68. doi: 10.1038/sj.mp.4001558.
- Husain, N., Mehmood, N., Husain, M., Kiran, T., Naeem, F., & Chaudhry, I., (2016). Feasibility study of culturally adapted cognitive behaviour therapy for psychosis in Pakistan. European Psychiatry, 33, S578–S579. doi: 10.1016/j.eurpsy.2016.01.2144.
- Jacobs, G, & Cohen, A. (2008). The South London and Maudsley NHS Foundation Trust and Oxleas NHS Foundation Trust Prescribing Guidelines. British Journal of Clinical Pharmacology, 65(4), 624–625. doi: 10.1111/j.1365-2125.2007.03051.x.
- Janoutová, J., Janáčková, P., Šerý, O., Zeman, T., Ambroz, P., Kovalová, M., et al. (2016). Epidemiology and risk factors of schizophrenia. Neuroendocrinology Letters, 37(1), 1?8.
- Jauhar, S., McKenna, P., Radua, J., Fung, E., Salvador, R., & Laws, K. (2014). Cognitive-behavioural therapy for the symptoms of schizophrenia: Systematic review and meta-analysis with examination of potential bias. The British Journal of Psychiatry, 204(1), 20–29. doi: 10.1192/bjp.bp.112.116285.
- Karakula-Juchnowicz, H., Juchnowicz, D., Krukow, P., Morylowska-Topolska, J., Pawezka, J., Flis, M., et al. (2016). Maternal obstetric complications and intellectual functioning in patients with schizophrenia and their healthy siblings. European Psychiatry, 33, S103–S1S4. doi: 10.1016/j.eurpsy.2016.01.080.
- Kay, S. R., Flszbein, A., & Opfer, L. A. (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13(2), 261.
- Keeley, J., & Gaebel, W. (2017). Symptom rating scales for schizophrenia and other primary psychotic disorders in ICD-11. Epidemiology and Psychiatric Sciences, 26. doi: 10.1017/S2045796017000270.
- Kring, A. M., & Gordon, A. H. (1998). Sex differences in emotion: Expression, experience, and physiology. Journal of Personality and Social Psychology, 74(3), 686.
- Leucht, S., Pitschel-Walz, G., Abraham, D., & Kissling, W. (1999). Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophrenia Research, 35(1), 51–68.
- Mendrek, A., & Mancini-Marïe, A. (2016). Sex/gender differences in the brain and cognition in schizophrenia. Neuroscience & Biobehavioral Reviews, 67, 57–78. doi: 10.1016/j.neubiorev.2015.10.013.
- Millan, M. J., Andrieux, A., Bartzokis, G., Cadenhead, K., Dazzan, P., Fusar-Poli, P., et al. (2016). Altering the course of schizophrenia: Progress and perspectives. Nature Reviews Drug Discovery, 15(7), 485–515. doi: 10.1038/nrd.2016.28.
- Morisky, D. E., Green, L. W., & Levine, D. M. (1986). Concurrent and predictive validity of a self-reported measure of medication adherence. Medical Care, 24(1), 67–74.
- Mortensen, P. B., Pedersen, C. B., Westergaard, T., Wohlfahrt, J., Ewald, H., Mors, O., et al. (1999). Effects of family history and place and season of birth on the risk of schizophrenia. New England Journal of Medicine. 340(8):603–608.
- Mortensen, P. B., Pedersen, M. G., Pedersen, C. B. (2010). Psychiatric family history and schizophrenia risk in Denmark: Which mental disorders are relevant? Psychological Medicine, 40(02), 201–210. doi: 10.1017/S0033291709990419.
- Riecher‐Rössler, A., Häfner, H. (2000). Gender aspects in schizophrenia: Bridging the border between social and biological psychiatry. Acta Psychiatrica Scandinavica, 102(s407), 58–62. doi: 10.1034/j.1600-0447.2000.00011.x.
- Robinson, D. G., Schooler, N. R., John, M., Correll, C. U., Marcy, P., Addington, J., et al. (2015). Prescription practices in the treatment of first-episode schizophrenia spectrum disorders: Data from the national RAISE-ETP study. American Journal of Psychiatry, 172(3), 237–248. doi: 10.1176/appi.ajp.2014.13101355.
- Seeman, M. V. (1982). Gender differences in schizophrenia. Canadian Journal of Psychiatry, 27(2), 107–112.
- Seeman, M. V. (2004). Gender differences in the prescribing of antipsychotic drugs. American Journal of Psychiatry, 161(8), 1324–1333. doi: 10.1176/appi.ajp.161.8.1324.
- Taj, R., & Khan, S. (2005). A study of reasons of non-compliance to psychiatric treatment. Dementia, 2, 5.
- Takahashi, S., Matsuura, M., Tanabe, E., Yara, K., Nonaka, K., Fukura, Y., et al. (2000). Age at onset of schizophrenia: gender differences and influence of temporal socioeconomic change. Psychiatry and Clinical Neurosciences, 54(2), 153–156. doi: 10.1046/j.1440-1819.2000.00651.x.
- Torniainen, M., Mittendorfer-Rutz, E., Tanskanen, A., Björkenstam, C., Suvisaari, J., Alexanderson, K., et al. (2015). Antipsychotic treatment and mortality in schizophrenia. Schizophrenia Bulletin, 41(3), 656–663. doi: 10.1093/schbul/sbu164.
- Walker, R., & Whittlesea, C. Clinical pharmacy and therapeutics. Amsterdam, Netherlands: Elsevier Health Sciences; 2011.